Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer

被引：0
|
作者：
Yoshitaka Saito
Yoh Takekuma
Yoshito Komatsu
Mitsuru Sugawara
机构：
[1] Hokkaido University Hospital,Department of Pharmacy
[2] Hokkaido University Hospital,Cancer Center
[3] Hokkaido University,Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences
来源：
International Journal of Clinical Oncology | 2023年 / 28卷
关键词：
Regorafenib; Severe hypertension; Metastatic colorectal cancer (mCRC); Vascular endothelial growth factor (VEGF); Progression-free survival; Multikinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1183 / 1190
页数：7
相关论文
共 50 条
  • [21] Vandetanib improves progression-free survival in lung cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (07) : 378 - 378
  • [22] Bevacizumab improves progression-free survival in ovarian cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (07) : 371 - 371
  • [23] Improved progression-free survival in metastatic breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (02): : E79 - E79
  • [24] Prolonged progression-free survival in metastatic breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (07) : 378 - 378
  • [25] Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
    Morgane Caulet
    Thierry Lecomte
    Olivier Bouché
    Jérôme Rollin
    Valérie Gouilleux-Gruart
    Nicolas Azzopardi
    Julie Léger
    Christophe Borg
    Jean-Yves Douillard
    Sylvain Manfredi
    Denis Smith
    Olivier Capitain
    Aurélie Ferru
    Driffa Moussata
    Eric Terrebone
    Gilles Paintaud
    David Ternant
    Clinical Pharmacokinetics, 2016, 55 : 1381 - 1394
  • [26] Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
    Caulet, Morgane
    Lecomte, Thierry
    Bouche, Olivier
    Rollin, Jerome
    Gouilleux-Gruart, Valerie
    Azzopardi, Nicolas
    Leger, Julie
    Borg, Christophe
    Douillard, Jean-Yves
    Manfredi, Sylvain
    Smith, Denis
    Capitain, Olivier
    Ferru, Aurelie
    Moussata, Driffa
    Terrebone, Eric
    Paintaud, Gilles
    Ternant, David
    CLINICAL PHARMACOKINETICS, 2016, 55 (11) : 1381 - 1394
  • [27] Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint
    Hurvitz, Sara A.
    CANCER TREATMENT REVIEWS, 2011, 37 (07) : 495 - 504
  • [28] Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment
    Yoshitaka Saito
    Yoh Takekuma
    Yoshito Komatsu
    Mitsuru Sugawara
    Supportive Care in Cancer, 2022, 30 : 10203 - 10211
  • [29] Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer
    Chirila, Costel
    Odom, Dawn
    Devercelli, Giovanna
    Khan, Shahnaz
    Sherif, Bintu N.
    Kaye, James A.
    Molnar, Istvan
    Sherrill, Beth
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (05) : 623 - 634
  • [30] Association of KRAS and BRAF mutations with progression-free survival (PFS) with second-line FOLFIRI plus /- regorafenib in metastatic colorectal cancer (mCRC)
    Innocenti, Federico
    Selitsky, Sara R.
    Parker, Joel S.
    Auman, James Todd
    Hammond, Kelli
    Patil, Sushant A.
    Sanoff, Hanna Kelly
    Lee, Michael Sangmin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345